Haleon shares issued 8,952,353,648; voting shares 8,906,422,686

Rhea-AI Filing Summary

Haleon plc reported its total voting rights and capital. As at 31 October 2025, the Company had 8,952,353,648 ordinary shares issued, including 45,930,962 held as treasury shares. After excluding treasury shares, the number of ordinary shares with voting rights is 8,906,422,686.

This voting-rights figure is the denominator shareholders and other obliged parties should use when assessing notification thresholds under the FCA’s Disclosure Guidance and Transparency Rules.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	03 November 2025 - “Total Voting Rights and Capital”

99.1

Haleon plc: Total Voting Rights and Capital

03 November 2025: As at 31 October 2025 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 8,952,353,648 ordinary shares of £0.01 each, of which 45,930,962 are held as treasury shares.

Therefore, the number of ordinary shares with voting rights is 8,906,422,686 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notifiable interests in Haleon may be sent to: company.secretary@haleon.com

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: November 03, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What is Haleon (HLN)'s total issued share count as at 31 October 2025?

Haleon had 8,952,353,648 ordinary shares issued as at 31 October 2025.

How many Haleon (HLN) shares were held in treasury?

Treasury shares totaled 45,930,962.

What is the number of Haleon (HLN) shares with voting rights?

The number of ordinary shares with voting rights is 8,906,422,686.

Which figure should HLN investors use for FCA DTR notifications?

Use 8,906,422,686 as the denominator for disclosure threshold calculations under the FCA’s DTR.

What is the reference date for Haleon’s voting rights update?

The figures are stated as at 31 October 2025.

Where can notifiable interests in Haleon be sent?

Send notifiable interests to company.secretary@haleon.com.